Opinion
The downside of pricing specialty pharmaceuticals too high
Most product managers in the biopharmaceutical industry lack background in health policy.
Why 'recall readiness' should be top-of-mind for every pharma exec
Given the heightened awareness of patient safety that FDA and industry managers have exerted in recent years, product recalls are a growing factor in operational performance.
Why community oncology matters
Oncology is the market for today's pipeline products. Here's why the community setting needs to be preserved as a primary site of care to administer those products
Managing the specialty pharmacy channel's evolution
Given the evolving dynamics of specialty pharmaceutical dispensing, manufacturers will need to master the evolving retail channel.
Focusing pharma marketing on 'headroom'
In the race to improve product performance, not enough attention is paid to 'who's actually going to switch?'
Pharma's stake in comparative effectiveness research
When drugs in development today hit the marketplace in 2020, they will need evidence of economic and clinical value results to be commercially successful
Liberating time in the Economy of Attention
Pharmaceutical marketing is now operating in a new landscape--the Economy of Attention
Tomorrow’s biopharma industry: new biotech products or higher operational efficiency--or both?
Abbott's spinout of AbbVie offers lessons
A managed services approach to sales and marketing
Applying the managed services model to commercial operations can result in dramatic savings as pharma companies globalize
BeSafeRx: FDA helping consumers avoid risks of online prescription drug purchases
 
1   2   3   Next
 
 
 
  
 
  
   
   
  |     |     |     |     |     |     |     |  
©2013 Pharmaceutical Commerce. All Rights Reserved.  |  Website managed and designed by OffWhite.